Breaking News Instant updates and real-time market news.

PCRX

Pacira

$30.68

-0.225 (-0.73%)

, HRTX

Heron Therapeutics

$27.30

5.8 (26.98%)

08:55
03/20/18
03/20
08:55
03/20/18
08:55

Pacira price target lowered to $42 after Heron data at Seaport Global

Seaport Global analyst Corey Davis noted that Heron Therapeutics (HRTX) reported positive results from its two Phase 3 studies of HTX-011 for postoperative pain in bunionectomy and herniorrhaphy. While Heron's HTX-011 data suggest some competition in 2020 for Pacira's (PCRX) Exparel, Davis said dose and volume "present problems" and that Heron "may run into a pricing problem" as well. He reiterates his Buy rating on Pacira shares, though he lowered his price target on the stock to $42 from $50, noting that he has formally removed nerve block revenue for Exparel entirely from his model after the negative FDA AdCom last month.

PCRX

Pacira

$30.68

-0.225 (-0.73%)

HRTX

Heron Therapeutics

$27.30

5.8 (26.98%)

  • 06

    Apr

PCRX Pacira
$30.68

-0.225 (-0.73%)

02/21/18
BMOC
02/21/18
NO CHANGE
Target $32
BMOC
Market Perform
Pacira Q4 sales momentum 'eased a bit' in January, says BMO Capital
BMO Capital analyst Gary Nachman notes Symphony data for January were released and show sales of Pacira Pharmaceuticals' Exparel of $23.2M, up a "healthy" 12.4% year-over-year. While the sales dropped 14.3% from December, January is normally lighter than December, Nachman tells investors in an intraday research note. Sales per selling day were below the levels for all Q4, the analyst notes, which he views as more concerning than the month-over-month decline. The analyst believes "some of the Exparel momentum" in Q4 "eased a bit" in January. He keeps a Market Perform rating on Pacira with a $32 price target.
03/01/18
HCWC
03/01/18
NO CHANGE
Target $45
HCWC
Buy
Pacira price target lowered to $45 from $55 at H.C. Wainwright
H.C. Wainwright analyst Oren Livnat lowered his price target for Pacira Pharmaceuticals to $45 after entirely removing the nerve-block indication for Exparel. The analyst, however, views the company's 2018 outlook as conservative and keeps a Buy rating on the shares.
03/01/18
RBCM
03/01/18
NO CHANGE
Target $44
RBCM
Outperform
Pacira price target lowered to $44 from $54 at RBC Capital
RBC Capital analyst Randall Stanicky lowered his price target on Pacira to $44 after Q4 earnings, saying the outlook for FY18 EXPAREL sales was below expectations. Stanicky keeps his Outperform rating on the stock, noting that the guidance is likely conservative and leaves some room for the upside in the upcoming updates.
03/19/18
JEFF
03/19/18
NO CHANGE
Target $30
JEFF
Buy
Heron pain drug 'hits a home run' in Phase III studies, says Jefferies
Jefferies analyst Biren Amin says Heron Therapeutics's (HRTX) HTX-011 "hits a home run" by meeting all primary and key secondary endpoints this morning from Phase III trials in bunionectomy and hernia repair. Safety looked clean in both studies, and HTX-011 produced durable pain reduction up to 72 hours and significant opioid sparing effect and differentiates from generic bupivacaine, Amin tells investors in a research note. The analyst believes HTX-011 should receive a superiority claim versus generic bupivacaine in its label for both bunionectomy and hernia surgery. Amin notes that Pacira's (PCRX) Exparel does not have this claim in its label. He assumes peak sales of $545M for HTX-011 and keeps a Buy rating on Heron with $30 price target.
HRTX Heron Therapeutics
$27.30

5.8 (26.98%)

03/02/18
LEER
03/02/18
NO CHANGE
Target $29
LEER
Outperform
Leerink ups Heron Therapeutics target to $29 after competitor setback
Leerink analyst Ami Fadia raised her price target for Heron Therapeutics (HRTX) to $29 from $27 after Tesaro (TSRO) announced earlier this week that it has withdrawn all promotional support for IV Varubi, based on numerous reports of anaphylaxis. Heron's Cinvanti, Tesaro's Varubi and Merck's (MRK) Emend are the only three branded NK-1 antagonists in the market today for chemo induced nausea and vomiting, Fadia tells investors in a research note. With Emend expected to go generic soon, Cinvanti will be the sole marketed branded agent, the analyst adds. She increased her 2023 estimate for Cinvanti from $150M to just under $200M and keeps an Outperform rating on Heron Therapeutics. The analyst continues to see upside for the stock ahead of the two Phase 3 trials for HTX-011 expected to read out in Q2.
03/20/18
MZHO
03/20/18
NO CHANGE
Target $35
MZHO
Buy
Heron Therapeutics price target raised to $35 from $28 at Mizuho
Mizuho analyst Difei Yang raised her price target for Heron Therapeutics to $35 citing yesterday's positive data from HTX-011 in two Phase 3 studies. The results demonstrate the superior product profile of HTX-011 in post-operative pain management compared to the current standard of care, Yang tells investors in a research note. She keeps a Buy rating on Heron shares.
03/20/18
NEED
03/20/18
NO CHANGE
Target $42
NEED
Buy
Heron Therapeutics price target raised to $42 from $30 at Needham
Needham analyst Serge Belanger raised his price target on Heron Therapeutics to $42 after the company's phase 3 trial results for HTX-011 on post-surgical pain management. The analyst says the treatment met all the primary and secondary endpoints while also demonstrating superiority over placebo and bupivacaine in terms of pain relief and opioid consumption. Belanger keeps his Buy rating on Heron Therapeutics, adding that the HTX-011 could be "game changer", with NDA filing coming in the second half of this year.

TODAY'S FREE FLY STORIES

YUMC

Yum China

$36.00

-0.8 (-2.17%)

20:46
07/19/18
07/19
20:46
07/19/18
20:46
Downgrade
Yum China rating change at BofA/Merrill »

Yum China downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 10

    Sep

MRSN

Mersana Therapeutics

$11.24

-5.275 (-31.95%)

20:45
07/19/18
07/19
20:45
07/19/18
20:45
Downgrade
Mersana Therapeutics rating change at Leerink »

Mersana Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$13.73

-0.02 (-0.15%)

, HON

Honeywell

$147.57

-1.58 (-1.06%)

20:25
07/19/18
07/19
20:25
07/19/18
20:25
Earnings
Notable companies reporting before tomorrow's openGentex »

Notable companies…

GE

General Electric

$13.73

-0.02 (-0.15%)

HON

Honeywell

$147.57

-1.58 (-1.06%)

SLB

Schlumberger

$66.91

-0.16 (-0.24%)

BHGE

Baker Hughes

$31.75

-0.79 (-2.43%)

STT

State Street

$92.84

-2.505 (-2.63%)

VFC

VF Corp.

$89.21

1 (1.13%)

STI

SunTrust

$69.00

-0.85 (-1.22%)

SWK

Stanley Black & Decker

$139.60

1.33 (0.96%)

RF

Regions Financial

$17.62

-0.43 (-2.38%)

CFG

Citizens Financial

$40.66

-0.365 (-0.89%)

KSU

Kansas City Southern

$108.48

1.93 (1.81%)

GNTX

Gentex

$23.41

-0.41 (-1.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

  • 20

    Jul

  • 20

    Jul

  • 20

    Jul

  • 20

    Jul

  • 20

    Jul

  • 20

    Jul

  • 20

    Jul

  • 20

    Jul

  • 20

    Jul

  • 20

    Jul

  • 20

    Jul

  • 08

    Aug

  • 19

    Oct

ISRG

Intuitive Surgical

$521.30

-6.37 (-1.21%)

20:11
07/19/18
07/19
20:11
07/19/18
20:11
Recommendations
Intuitive Surgical analyst commentary  »

Intuitive Surgical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 21

    Aug

  • 27

    Aug

CDNS

Cadence Design

$45.24

-0.29 (-0.64%)

20:04
07/19/18
07/19
20:04
07/19/18
20:04
Hot Stocks
Cadence Design announces Sigrity 2018 release »

Cadence Design announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

AVA

Avista

$50.40

0.06 (0.12%)

19:33
07/19/18
07/19
19:33
07/19/18
19:33
Hot Stocks
Idaho Public Utilities Commission postpones Avista and Hydro One merger hearing »

Hydro One Limited and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

CRK

Comstock Resources

$11.35

-0.2 (-1.73%)

19:28
07/19/18
07/19
19:28
07/19/18
19:28
Hot Stocks
Comstock Resources acquires Haynesville shale assets for $31M »

Comstock Resources, …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

GRPN

Groupon

$4.76

0.04 (0.85%)

, IBM

IBM

$149.25

4.81 (3.33%)

19:16
07/19/18
07/19
19:16
07/19/18
19:16
Periodicals
Groupon lawyer says IBM shakes down other tech companies, Reuters says »

A lawyer for Groupon…

GRPN

Groupon

$4.76

0.04 (0.85%)

IBM

IBM

$149.25

4.81 (3.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

WDC

Western Digital

$77.45

-1.33 (-1.69%)

19:06
07/19/18
07/19
19:06
07/19/18
19:06
Hot Stocks
Western Digital begins sampling 1.33 terrabit 3D NAND »

Western Digital announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

CE

Celanese

$109.84

-1.17 (-1.05%)

, LLNW

Limelight Networks

$4.69

-0.04 (-0.85%)

19:04
07/19/18
07/19
19:04
07/19/18
19:04
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

CE

Celanese

$109.84

-1.17 (-1.05%)

LLNW

Limelight Networks

$4.69

-0.04 (-0.85%)

ISRG

Intuitive Surgical

$521.30

-6.37 (-1.21%)

MSFT

Microsoft

$104.70

-0.38 (-0.36%)

SWKS

Skyworks

$102.46

0.41 (0.40%)

COF

Capital One

$95.32

-1.77 (-1.82%)

ETFC

E-Trade

$61.20

-1.94 (-3.07%)

PTCT

PTC Therapeutics

$36.61

1.59 (4.54%)

RWT

Redwood Trust

$16.64

0.135 (0.82%)

AEP

American Electric

$70.65

0.41 (0.58%)

WEC

WEC Energy

$65.23

0.51 (0.79%)

SKX

Skechers

$33.24

0.61 (1.87%)

FTD

FTD Companies

$4.52

0.06 (1.35%)

ZYNE

Zynerba

$10.40

0.24 (2.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 20

    Jul

  • 25

    Jul

  • 02

    Aug

  • 08

    Aug

  • 08

    Aug

  • 14

    Aug

  • 21

    Aug

  • 27

    Aug

  • 04

    Sep

  • 20

    Jul

BG

Bunge

$67.99

-0.43 (-0.63%)

19:04
07/19/18
07/19
19:04
07/19/18
19:04
Periodicals
Bunge in talks to sell part of sugar trading unit to Wilmar, Bloomberg says »

Bunge is in discussions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

PEG

PSEG

$52.18

0.42 (0.81%)

18:42
07/19/18
07/19
18:42
07/19/18
18:42
Downgrade
PSEG rating change at Goldman Sachs »

PSEG downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEC

WEC Energy

$65.23

0.51 (0.79%)

18:41
07/19/18
07/19
18:41
07/19/18
18:41
Upgrade
WEC Energy rating change at Goldman Sachs »

WEC Energy upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEP

American Electric

$70.65

0.41 (0.58%)

18:41
07/19/18
07/19
18:41
07/19/18
18:41
Upgrade
American Electric rating change at Goldman Sachs »

American Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

ETR

Entergy

$80.97

0.465 (0.58%)

18:40
07/19/18
07/19
18:40
07/19/18
18:40
Upgrade
Entergy rating change at Goldman Sachs »

Entergy upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLY

Eli Lilly

$89.45

-0.6 (-0.67%)

, INCY

Incyte

$70.10

-0.3 (-0.43%)

18:33
07/19/18
07/19
18:33
07/19/18
18:33
Hot Stocks
Lancet study shows benefit of Baricitinib 4 mg for treatment of SLE »

Eli Lilly (LLY) and…

LLY

Eli Lilly

$89.45

-0.6 (-0.67%)

INCY

Incyte

$70.10

-0.3 (-0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 31

    Jul

  • 10

    Sep

T

AT&T

$31.27

-0.46 (-1.45%)

18:20
07/19/18
07/19
18:20
07/19/18
18:20
Periodicals
U.S. court clears expedited appeal of AT&T-Time Warner deal, Reuters says »

A federal appeals court…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 09

    Aug

VLKAY

Volkswagen

$0.00

(0.00%)

18:17
07/19/18
07/19
18:17
07/19/18
18:17
Periodicals
VW to furlough roughly 1,000 workers at biggest factory in Brazil, Reuters says »

Volkswagen intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,187.14

-8.67 (-0.73%)

, GOOGL

Alphabet Class A

$1,199.26

-13.38 (-1.10%)

18:09
07/19/18
07/19
18:09
07/19/18
18:09
Periodicals
Google faces uphill but not insurmountable fight to appeal EU fine, WSJ says »

Google (GOOG) parent…

GOOG

Alphabet

$1,187.14

-8.67 (-0.73%)

GOOGL

Alphabet Class A

$1,199.26

-13.38 (-1.10%)

INTC

Intel

$52.01

0.3 (0.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 23

    Jul

  • 08

    Aug

  • 14

    Aug

  • 18

    Sep

  • 28

    Oct

NWE

NorthWestern

$58.29

0.56 (0.97%)

18:03
07/19/18
07/19
18:03
07/19/18
18:03
Earnings
Breaking Earnings news story on NorthWestern »

NorthWestern reaffirms…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

MSFT

Microsoft

$104.70

-0.38 (-0.36%)

18:03
07/19/18
07/19
18:03
07/19/18
18:03
Hot Stocks
Breaking Hot Stocks news story on Microsoft »

Microsoft up 4.4%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 08

    Aug

  • 08

    Aug

  • 04

    Sep

NWE

NorthWestern

$58.29

0.56 (0.97%)

18:03
07/19/18
07/19
18:03
07/19/18
18:03
Earnings
NorthWestern reports Q2 EPS 87c, consensus 47c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

MSFT

Microsoft

$104.70

-0.38 (-0.36%)

18:02
07/19/18
07/19
18:02
07/19/18
18:02
Hot Stocks
Microsoft sees Q1 effective tax rate slightly lower »

Sees Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 08

    Aug

  • 08

    Aug

  • 04

    Sep

CVX

Chevron

$121.72

0.17 (0.14%)

, BP

BP

$44.44

0.2 (0.45%)

17:58
07/19/18
07/19
17:58
07/19/18
17:58
Periodicals
Judge dismisses NYC climate lawsuit against oil majors, Reuters reports »

U.S. District Judge John…

CVX

Chevron

$121.72

0.17 (0.14%)

BP

BP

$44.44

0.2 (0.45%)

COP

ConocoPhillips

$69.70

-0.65 (-0.92%)

XOM

Exxon Mobil

$82.01

-0.22 (-0.27%)

RDS.A

Royal Dutch Shell

$69.17

0.27 (0.39%)

RDS.B

Royal Dutch Shell

$72.44

0.14 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 27

    Jul

MSFT

Microsoft

$104.70

-0.38 (-0.36%)

17:58
07/19/18
07/19
17:58
07/19/18
17:58
Hot Stocks
Breaking Hot Stocks news story on Microsoft »

Microsoft sees FY19 tax…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 08

    Aug

  • 08

    Aug

  • 04

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.